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Abstract
Analysis of the changing mRNA expression profile of Mycobacterium tuberculosis though the
course of infection promises to advance our understanding of how mycobacteria are able to
survive the host immune response. The difficulties of sample extraction from distinct
mycobacterial populations, and of measuring mRNA expression profiles of multiple genes has
limited the impact of gene expression studies on our interpretation of this dynamic infection
process. The development of whole genome microarray technology together with advances in
sample collection have allowed the expression pattern of the whole M. tuberculosis genome to be
compared across a number of different in vitro conditions, murine and human tissue culture
models and in vivo infection samples. This review attempts to produce a summative model of the
M. tuberculosis response to infection derived from or reflected in these gene expression datasets.
The mycobacterial response to the intracellular environment is characterised by the utilisation of
lipids as a carbon source and the switch from aerobic/microaerophilic to anaerobic respiratory
pathways. Other genes induced in the macrophage phagosome include those likely to be involved
in the maintenance of the cell wall and genes related to DNA damage, heat shock, iron
sequestration and nutrient limitation. The comparison of transcriptional data from in vitro models
of infection with complex in vivo samples, together with the use of bacterial RNA amplification
strategies to sample defined populations of bacilli, should allow us to make conclusions about M.
tuberculosis physiology and host microenvironments during natural infection.
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INTRODUCTION
The mycobacterial transcriptome consists of the mRNA content of bacilli in a particular
environment at a specific time. This represents, subject to additional levels of mRNA and
protein regulation, the products required by mycobacteria for continued survival. Little is
known of the events that occur at the gene expression level in host tissues after infection
with Mycobacterium tuberculosis. However the development of techniques such as
subtractive hybridisation, quantitative RT-PCR and microarray technologies have allowed
the transcriptional responses of both host and pathogen to be explored during infection. Thus
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it is possible to determine the immediate genome-wide response (as measured by mRNA
expression) of mycobacteria to a stimulus or environment. The comparison of mycobacterial
mRNA expression patterns from intracellular infection models provides a snapshot of the
network of interactions between bacilli and the external environment. These transcriptional
datasets can be used to (a) help understand the changing metabolism of infecting bacilli,
which may in turn provide insights into the host microenvironments encountered by bacilli;
(b) identify pathogenic mechanisms used by M. tuberculosis to evade and modulate the
immune response; and (c) define the interactions between host and pathogen throughout the
multi-factorial and dynamic process of infection. This review outlines the mycobacterial
response to infection derived from the mRNA expression patterns of M. tuberculosis
extracted from intracellular environments.
M. tuberculosis Pathogenesis
The complex pathogenesis of M. tuberculosis is influenced by a multitude of factors
including host and bacterial genetic backgrounds, immunological status and environmental
circumstances. The earliest encounter between infecting bacilli and the immune system is
likely to be with alveolar macrophages; that some bacilli survive this initial contact provides
a relevant starting point to begin investigating host-M. tuberculosis interactions.
Primary infection with M. tuberculosis takes place in the lungs, and may eventually result in
pulmonary tuberculosis; however only 5-10% of those individuals infected actually develop
clinical disease [1]. On infection a proportion of infecting bacilli are able to survive and
successfully multiply within the intracellular environment of the alveolar macrophage. A
fundamental step in mycobacterial survival is the halt of phagosome maturation in
macrophages after phagocytosis of M. tuberculosis [2]. The bacilli therefore avoid
destruction in the fused phagolysosome by acidic hydrolases [3], with the pH of
mycobacterial-containing phagosomes remaining at 6.5 [4]. Characterisation of the surface
markers of M. tuberculosis-containing phagosomes reveal that many markers of early
endosomes and from the plasma membrane are present, for example mycobacterial
phagosomes retain the Rab5 molecule but do not acquire the late endosomal marker Rab7,
which is believed to be involved in the transition from early to late endosome [5]. Successful
control of M. tuberculosis infection is achieved in the lung by the formation of granulomas,
where activated macrophages surround the site of infection preventing further dissemination
of bacilli and limiting tissue damage [6]. The human granuloma consists of many different
cell types including macrophages, giant cells, fibroblasts, T cells and B cells [7], and
requires the orchestration of a range of chemokines, cytokines, adhesins and integrins to
coordinate the recruitment, migration and retention of cells to the granuloma [8]. A balance
is reached where the mycobacterial infection has been controlled, but the bacilli inside the
granuloma have not been destroyed [9]. This situation continues until the immunological
balance is shifted in such a way that allows the bacilli to begin successfully multiplying
again resulting in pulmonary disease [10].
The immuno-modulatory capacity of M. tuberculosis at the interface of bacilli and
macrophage has been established for example by the secretion of eukaryotic-like protein
kinase G by mycobacteria within the macrophage phagosome [11], and the demonstration
that mycobacterial lipids and proteins are trafficked out of infected phagosomes and into
uninfected bystander macrophages [12]. The dynamic interaction between mycobacteria and
host immune system is also exemplified by the variable contributions of immune cell surface
receptors (e.g. TLR receptors) to the successful control of M. tuberculosis at different stages
of infection [13]. Further characterisation of the cross-talk between host immune system and
M. tuberculosis may reveal novel virulence mechanisms and suggest future innovative
treatment strategies.
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The metabolic state of bacilli through the course of human infection is largely unknown,
especially that of persistent bacilli. However, transcriptional activity has been detected in
persistent mycobacteria from in vivo murine models of infection using RT-PCR [14, 15].
The inference that persistent bacilli are metabolically active in some way is especially
important in the design of new drugs against M. tuberculosis [16]. The significance of
mycobacterial persistence and drug tolerance has been reviewed by Gomez and McKinney
[17]. What is clear however is that the metabolic state of infecting bacilli is likely dependent
on a number of factors including the oxygen tension and tissue structure of the surrounding
environment in the human lung [18, 19].
A greater understanding of how mycobacteria are able to survive the complex environments
encountered during infection will aid novel treatment strategies targeted more specifically at
intracellular or persistent bacilli. Expression analyses have the power to inform us how the
infecting bacilli are responding to the environments in which they reside, telling us a little
about the different niches that mycobacteria occupy and how they are able to adapt. The
interactions between M. tuberculosis and macrophage have been reviewed recently by
Schnappinger at al. [20]; McKinney and Gomez [21]; and the immunology of M.
tuberculosis control is described in detail by Flynn and Chan [7]; and Kaufmann [22]. This
review focuses on the mycobacterial transcriptional response to the intracellular
environment during early infection, and how the expression profile of M. tuberculosis might
change with the progression of disease.
The M. tuberculosis Transcriptional Response to the Intracellular Environment
The understanding of mycobacterial interactions with the host has been enhanced by
expression studies using (a) in vitro models, such as how bacilli respond to microaerophilic
conditions [23, 24], as reviewed by Bacon and Marsh in this issue; (b) tissue culture models
of M. tuberculosis infection using murine or human derived macrophages [25, 26]; (c)
animal models such as the murine model of M. tuberculosis disease [27]; and (d) from
human patient samples [19]. Here we review the limited expression data available from
intracellular models of infection, concentrating on the studies using whole genome
expression analyses but also incorporating data from quantitative RT-PCR, in situ
hybridisation, promoter trap and subtractive/enrichment hybridisation methodologies. Table
(1) details the publications to date that have looked at the in vivo expression of multiple M.
tuberculosis genes, as opposed to mutant or essentiality studies. Mycobacterial gene
expression patterns identified in tissue culture or in vitro models of infection enable us to
dissect out the complex interactions between pathogen and host. We review M. tuberculosis
expression profiles derived from macrophage infection models in comparison with in vivo
transcriptional data. Gene expression data may be classified and interrogated by functional
category, chromosome position or overlaid onto metabolic pathways. This third approach is
the most informative, helping to define the physiological state of infecting mycobacteria,
and has been adopted here wherever possible. The major metabolic themes of intracellular
M. tuberculosis gene expression are detailed below and depicted in Fig. (1).
β-Oxidation of Fatty Acids
The induction of multiple genes in four of the five reactions required for the β-oxidation of
fatty acids (fadD3, 9, 10, 19, fadDE5, 14, 22, 23, 24, 27, 28, 29, 31, echA19, fadB2, 3,
fadA5, 6), and the subsequent metabolism of degradation products via the citric and
glyoxylate cycles (icl, gltA1, Rv1130) suggests that M. tuberculosis utilises a diverse range
of fatty acids as a carbon source during intraphagosomal growth [25, 28]. The induction of
these genes involved in fatty acid metabolism on infection of macrophages indicates that the
phagosomal compartment that bacilli occupy in at least one stage of infection is low in other
sources of carbon such as glucose and glycerol [29]. In addition the up-regulation of pckA,
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encoding a phosphoenolpyruvate carboxykinase, reveals that fatty acids may be converted
through gluconeogenesis into sugars. Genes in these fatty acid metabolism pathways
(namely icl and pckA) have also been shown by RT-PCR [30] and microarray analysis [27]
to be induced in the mouse lung after infection, and within artificial murine granulomas
[31]. The up-regulation of icl has also been described on infection of human-derived
macrophage-like cells, using SCOTS [32] and subtractive hybridisation [33], and inside non-
necrotic human lung granulomas by in situ hybridisation [18]. The source of these fatty
acids is unknown; it may be that the smorgasbord of complex lipids generated by M.
tuberculosis is utilised, or host lipids, or a combination of the two depending on the
particular microenvironment in which the bacilli find themselves. This pattern of fatty acid
utilisation does however appear to be common to all infection models tested. It may
therefore represent a fundamental adaptation to intracellular growth and an important target
pathway for M. tuberculosis drug development.
Respiratory State
Transcriptional changes have been identified in the aerobic and anaerobic respiratory
pathways of M. tuberculosis during infection. Genes related to aerobic respiration such as
the type I NADH dehydrogenase (nuoABDFIL), and cytochrome C reductase (qcrC) were
identified to be repressed inside the macrophage phagosome; in contrast genes encoding
products involved in alternative electron acceptor pathways (frdA a fumarate reductase,
narX a nitrate reductase and ndh a type II NADH dehydrogenase) were induced [25]. A
similar profile of gene expression has been described in the mouse lung during infection by
molecular beacon RT-PCR and has lead Shi et al. [34] to propose that M. tuberculosis may
exist in three different respiratory states depending on the microenvironment encountered.
During acute infection the energy-efficient type I NADH dehydrogenase (exemplified by the
expression of nuoB) together with the aa3-cytochrome C complex (assayed by following the
expression of qcrC and ctaD) as a terminal oxidase is utilised. Immune cell activation
leading to the generation of nitric oxide blocks this aerobic respiratory pathway and drives
M. tuberculosis into a transitional respiratory state characterised by the repression of the aa3
cytochrome C terminal oxidase complex (qcrC, ctaD) and induction of the bd-type terminal
oxidase (exemplified by the expression of cydA) and nitrate respiration (assayed by
following the expression of narK2). During chronic murine infection the bd-type terminal
oxidase is down-regulated and nitrate is used as the final electron acceptor [34]. This pattern
is also reflected in the expression of the dosR regulon, a set of around 50 genes induced by
hypoxia [23, 35] and nitric oxide treatment [36]. This regulon was induced in M.
tuberculosis after stimulation of murine macrophages with IFNγ and was dependent on the
presence of a functioning murine NOS2 enzyme [25]. The up-regulation of dosR and around
20 other members of the regulon was also demonstrated within artificial murine granulomas
[31]. Furthermore induction of the dosR regulon (assayed using the expression of hspX,
Rv2623 and Rv2626c) was described to occur in the mouse lung as bacterial numbers began
to fall following the induction of the adaptive immune response [37]; a similar profile was
also observed for the expression of Rv1738, fdxA, acg, hspX and Rv2626c in the murine
lung [36]. Therefore the dosR regulon, mediated by nitric oxide (and/or hypoxia), is induced
in the murine model of infection on activation of the immune response and may be part of a
mycobacterial response that leads to persistence in the host. The respiratory and metabolic
status of persistent bacilli has recently been comprehensively reviewed by Boshoff and
Barry [38].
The respiratory state of bacilli during human disease is less well documented. The
expression of narX coding for a probable nitrate reductase was demonstrated to be expressed
in M. tuberculosis located in human non-necrotic granulomas [18, 19]; the nitrate reductases
narX, narG and the fumarate reductase, frdA were also found to be induced in the human
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pericavity and distant lung of tuberculosis patients [19]. Additionally the induction of both
aerobic and anaerobic genes in human lung tissue [19] suggests that the respiratory status of
infecting bacilli is dependent on the microenvironment encountered. The induction of the
dosR regulon has not been fully demonstrated in human infection, although hspX has been
reported to be up-regulated in the human lung [30]. The role of nitric oxide in the control of
M. tuberculosis infection in man is unclear, however the ability of M. tuberculosis to utilise
several respiration pathways and the induction of alternative electron acceptors during
infection provide possible drug development targets. Transcriptomic analysis of smaller
more distinct populations of bacilli during natural infection may help to elucidate the
variable respiratory state of M. tuberculosis in the human lung.
Inextricably linked to respiration state are the energy requirements of the infecting bacilli;
genes encoding ATP synthase subunits (atpABD-H) were down-regulated in the murine
macrophage phagosome and this pattern was repeated in naïve, IFNγ -activated or NOS2-
deficient macrophages compared to in vitro growth [25]. Furthermore atpA and atpD were
repressed during chronic infection of immuno-competent mice [34]. This repression of ATP-
synthases in vivo is likely to simply reflect the different energy demands of bacilli growing
logarithmically in vitro or inside the macrophage phagosome. However the differential
regulation of genes encoding ATP synthase subunits may be involved in the maintenance of
intracellular pH, or may represent the sudden requirement for metabolic activity as the
bacilli adapt to a changing environment. This may explain the induction of atpE/F/H at 21
days after infection of immuno-competent compared to severe-immuno deficient (SCID)
mice as the bacilli respond to the adaptive immune challenge in the immuno-competent
environment [27].
Iron Sequestration
The lack of available iron during infection is a problem encountered by many pathogens,
which is further exploited by the induction of iron-sequestering complexes as part of the
host immune response [39]. M. tuberculosis genes involved in the generation of mycobactin,
a siderophore-like iron-binding molecule (mbtA-J) were identified to be induced in IFNγ-
activated murine macrophages [25]; a subset of genes up-regulated in low iron conditions
were also induced in naïve murine macrophages. The induction of genes involved in the
control of mycobacterial iron sequestration and storage has also been demonstrated to occur
during murine infection; Timm et al. [30] reported the induction of mbtB in murine lungs,
which coincided with the control of bacterial growth by the immune response. In addition
the expression of bfrA (encoding an iron-storing bacterioferritin) was down-regulated [30].
This gene expression profile correlates well with the up-regulation of mbtD (involved in
mycobactin synthesis), hupB (coding for an iron-regulated protein), and fdxA (encoding
ferredoxin) at 21 days post infection in immuno-competent compared to severely immuno-
deficient mice [27]. The M. tuberculosis genes mbtB, mbtI and Rv3402c regulated by IdeR
(an iron-dependent regulator) were also induced on infection of human macrophage-like
THP-1 cells [40]. Furthermore furB, encoding a probable ferric/zinc uptake regulator was
also up-regulated on THP-1 infection [41]. The relative increase in the expression of genes
involved in iron sequestration in activated macrophages (or immuno-competent mice)
suggests that the bacilli find themselves in an iron-limited environment after immune
activation, or that the mycobacterial requirement for iron increases in the microenvironment
in which the bacilli reside.
In addition to iron, other moieties required for successful mycobacterial growth are likely to
be limited at various stages of infection. Rachman et al. [19] observed an induction of amino
acid transport-related genes in M. tuberculosis infected human lung sections. Indeed a
number of genes identified to be induced by nutrient starvation were also demonstrated to be
up-regulated after infection of naïve or activated murine macrophages [42, 25]. The
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requirement of relA (encoding (p)ppGpp synthase and hydrolase activities) as part of the
stringent response has been demonstrated in long-term anaerobic models [43] and during
murine infection [31]. A comparison of the expression profiles of a relA knockout mutant
with WT M. tuberculosis under starvation conditions has identified around 160 genes that
may be regulated by (p)ppGpp, including genes involved in anaerobic respiration (narH,
narI) and fatty acid metabolism (aceAb, acpM, fas, kasA, kasB) [44]. Further exploration of
the mycobacterial stringent response may reveal insights into how M. tuberculosis bacilli are
able to adapt to nutrient-limited surroundings during infection.
Mycobacterial Lipid Moieties
The mycobacterial cell wall acts as the interface between the infecting bacilli and the host
environment, therefore it is unsurprising to find genes involved in the synthesis and
modification of cell wall associated fatty acids up-regulated in vivo. Genes involved in
mycolic acid modification (desA1/2 and umaA) were found to be induced inside the murine
phagosome [25]. Additionally the desaturases encoded by desA1 and desA3 were up-
regulated in infected human lung together with mmaA3/A4 and umaA [19]. The induction
of these genes is likely connected with the maintenance of the hydrophobic nature of the cell
wall barrier from damage during macrophage infection. A second set of genes coding for
polyketide synthases involved in the biosynthesis of mycobacterial complex lipids have also
been demonstrated to be induced during macrophage infection. Mycocerosic acid synthase
(mas) and the related genes fadD28 [41] and fadD26 [25] were up-regulated in the
macrophage phagosome; these gene products are part of the biosynthetic pathway of
phthiocerol dimycocerosate which is required for successful mycobacterial infection [45]. In
addition the induction of pks2 [32], necessary for sulpholipid generation [46], and pks6 [33],
involved in the expression of an unknown polar lipid [47], in human macrophages further
highlights the potential importance of mycobacterial complex lipids during infection.
Whether these lipid moieties are part of a response to strengthen the lipid-rich mycobacterial
cell wall, or play a more active role in host-pathogen interactions is currently unknown [12].
DNA Repair
Mycobacterial genes involved in DNA recombination and repair were up-regulated in the
intraphagosomal environment of both naïve and activated murine macrophages (alkA, recX,
recC, dinF and radA). Interestingly this pattern of gene expression was also observed on
infection of NOS2-deficient macrophages, indicating that the probable M. tuberculosis
response to DNA damage occurs in the absence of nitric oxide [25]. A similar subset of
genes mfd, dinF/G and polA were also induced on murine macrophage infection [28].
Furthermore genes involved in mycobacterial DNA repair have also been demonstrated to
be up-regulated on infection of human macrophages (uvrA) [32], and the human lung (dinX,
dinF, gyrA/B) [19].
Molecular Chaperones
The induction of molecular chaperones involved in the folding and translocation of
polypeptides has been observed in M. tuberculosis under a number of stress conditions,
exemplified by the heat shock response [48]. Rachman et al. [19] identified a number of
genes related to chaperone biosynthetic pathways (groEL/ES, suhB, dnaJ1/2, dnaK, hspR
and hspX) to be up-regulated in the human lung during M. tuberculosis infection. Similarly
the induction of groEL2 was reported after infection of human macrophage cell lines [41].
The activation of genes coding for molecular chaperones and DNA repair proteins may be
part of a common stress response induced by multiple stimuli, for example different drug
treatments [49, 50], the details of which are yet to be elucidated.
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Antigen Expression
The induction of genes encoding members of the highly immunogenic PE/PE-PGRS and
PPE families in vivo was demonstrated in human pulmonary tissue [19] and murine
macrophages [25]. Interestingly the induction of some PE/PPE genes occurs alongside the
repression of others in both macrophage and murine models [51], and this pattern of PE/PPE
differential expression is repeated across many different growth/stress conditions [52]. The
functional significance of these gene families, which command approximately 10% of the
coding capacity of M. tuberculosis H37Rv is uncertain [53], however there is evidence that
some of these proteins are found at the cell surface and may mediate interactions with the
host [54]. Elucidation of the expression pattern of these genes, which may act as variable
surface antigens during infection [55], may influence future vaccine design strategies. Other
potential M. tuberculosis antigens such as members of the ESAT-6 family (esxH, esxO,
esxV) were also identified to be expressed in the murine lung [56]. Shi et al. [57] identified
differences in the transcription of genes encoding M. tuberculosis secreted antigens
throughout murine lung infection, and Dahl et al. [44] have reported that the expression of
many of these antigenic proteins may be under the control of relA as part of the
mycobacterial stringent response. These observations highlight how gene expression
approaches may be used to supplement antigenic studies and influence vaccine design
strategy.
The Regulation of Mycobacterial In Vivo Gene Expression
A greater understanding of the regulation of M. tuberculosis gene expression may be gained
by looking at the differential expression of genes known to control mycobacterial
transcription. The induction of low iron responsive (ideR) and heat shock responsive (hspR)
transcriptional regulators are likely at least in part to coordinate the expression of iron
sequestration factors and molecular chaperones as discussed above. The transcription factors
sigB and sigE were found to be induced in the murine phagosome [25]. One possible
stimulus for the increased expression of these regulatory proteins has been demonstrated to
be cell wall stress (treatment with detergent [58]), something that is likely to be relevant
throughout infection. Furthermore sigB, sigC and sigH were observed to be up-regulated
within artificial murine granulomas [31] and sigE, sigG and sigH have been demonstrated to
be induced inside human macrophages [26, 32]. In addition, the regulatory proteins sigF and
sigL may also be necessary for successful in vivo survival [33, 59, 60]. The up-regulation of
a number of two component systems in vivo has also been reported, including dosR which
mediates the M. tuberculosis response to hypoxia [23], and which is induced together with
much of its regulon inside artificial murine granulomas [31] as previously described.
Moreover the expression of mtrA, regX3, phoP, prrA, mprA, kdpE, trcR and tcrX have all
been detected after infection of human-derived macrophages with M. tuberculosis [61, 62].
Further characterisation of the gene subsets controlled by these global regulators and of the
stimuli that influence their expression will help reveal the networks of gene regulation
required for M. tuberculosis pathogenicity.
What the M. tuberculosis Intracellular Transcriptome Can Tell us About the Phagosomal
Environment
The comparison of expression data from in vitro and in vivo models is a valuable tool in
understanding both the nature of the intracellular environment that M. tuberculosis
encounters during infection and how bacilli respond to these stresses. By comparing
overlapping gene expression patterns from in vitro and in vivo models it is possible to
speculate on the conditions that infecting bacilli face. The phagosomal environment of naïve
macrophages is likely to be low in glucose or glycerol based carbon sources, low in amino
acids, and low in iron as compared to nutrient starvation and low iron in vitro conditions
[42, 63, 64]. On activation (of murine macrophages with IFNγ) the bacilli are likely to be
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exposed to nitric oxide, oxidative stress and possibly a hypoxic environment [25], although a
shift to anaerobic respiration in bacilli may be due to the presence of NO, rather than the
absence of oxygen [36]. Schnappinger et al. [25] defined 68 genes that were preferentially
induced after infection of IFNγ-activated compared to naïve murine macrophages. Nearly
half of these genes were identified as part of the dosR regulon, a set of around 50 genes
induced by hypoxia [23, 35] and nitric oxide treatment [36]. Additionally many of the
activation-specific genes were also up-regulated by nitric oxide or hydrogen peroxide
treatment in vitro, and the induction of these genes was not observed in NOS2-deficient
macrophages [25]. A subset of iron-responsive genes was also induced to a greater degree in
activated murine macrophages. The intraphagosomal M. tuberculosis expression profile also
encompasses subsets of genes that have been characterised as part of the mycobacterial
responses to various stresses, such as DNA damage, detergent treatment, low pH and heat
shock [48, 58, 65, 66]. A summary of the possible microenvironments that M. tuberculosis
encounters during infection is depicted in Fig. (2).
Mycobacterial gene expression is regulated by many factors and controlled by a complex
network of sensory systems and feedback loops. It is clear that some pathways are induced
by multiple stimuli; for example genes associated with the mycobacterial response to low
iron are also induced by nitric oxide, H2O2 or hypoxia [25, 35]. Furthermore the expression
of dosR (integeral to the M. tuberculosis response to macrophage activation and persistence
as modelled in vitro) is induced by hypoxia, nitric oxide (s-nitrosoglutathoine), ethanol and
H2O2 treatments but not heat or cold-shock [67]. Further investigation is required to identify
which environmental conditions are influencing M. tuberculosis gene expression in an effort
to better understand the multi-factorial infection process.
INFECTION MODELS AND MAN
The comparison of M. tuberculosis gene expression profiles from tissue culture models
derived from murine or human sources is challenging. This is partly due to differences in the
survival of bacilli after macrophage infection between murine and human models.
Schnappinger et al. [25] described little or no growth of M. tuberculosis in naïve murine
bone marrow macrophages and a decrease in mycobacterial survival after 72 h in IFNγ-
activated macrophages, compared to successful M. tuberculosis growth in human-derived
monocytes and THP-1 cells [68, 69]. This may be due to variation in immunologically
relevant elements, such as TLR expression [70], or the production of antimicrobial moeities
such as nitric oxide. Indeed the role of nitric oxide in the control of human mycobacterial
infection has been controversial; although it is likely that nitric oxide does play some part in
the human immune response to M. tuberculosis [71]. The induction of nitric oxide from cells
in vitro may however depend on where and how the immune cells were extracted, matured
and infected [72].
The extrapolation of expression data from tissue culture models to animal models and
natural M. tuberculosis infection is obviously complicated by many factors. Amongst the
most apparent are the sampling of broad populations of bacilli from different
microenvironments from in vivo infection models and the differences in pathology between
murine and human infection [73]. There are however many similarities to be drawn between
the mycobacterial responses to macrophage activation (derived from tissue culture models)
and responses to the onset of the adaptive immune system in murine lungs; as expression
profiling methods progress it should be possible to further explore human M. tuberculosis
infection.
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CONCLUSIONS
The transcriptional response of M. tuberculosis to the intracellular environment has
highlighted a number of mechanisms that mycobacteria may utilise to successfully survive
in vivo. This transcriptional data has also revealed a little about the microenvironments that
bacilli may encounter. The future comparison of expression patterns from distinct
mycobacterial populations from in vivo, tissue culture and in vitro models of infection
promises to uncover a great deal more about M. tuberculosis pathogenesis, which will
hopefully lead to novel treatment strategies.
One of the most exciting features of transcriptional profiling using DNA microarrays is the
expression data obtained for genes of unknown function that would be overlooked using a
bottom-up experimental strategy. As more microarray datasets become available the co-
expression of genes encoding hypothetical proteins with known transcriptional pathways
may allow novel gene functions to be described and explored. The transcriptional data
discussed herein mostly concerns the induction of mycobacterial transcription. Nevertheless
the repression of genes may be just as important for the outcome of host pathogen
interactions during infection, as described recently for regulation of the mce1 operon in
murine macrophages [74]. The expression of mycobacterial genes discussed in this review is
(in most cases) relative to in vitro logarithmically growing bacilli; this comparison
highlights the differences between logarithmic growth in complete media and in vivo growth
but does not necessarily reveal which mechanisms are key to mycobacterial survival (as
discussed [75]), or indeed how essential particular genes are for successful infection. This
review has focused purely on the mRNA expression data available for the intracellular
survival of M. tuberculosis, ignoring the huge arsenal of data on the functional significance
of particular genes using techniques such as signature tag mutagenesis [76, 77], and
knockout/down studies [78, 79]; and of course areas including mRNA degradation, protein
expression, processing and regulation.
We are currently able to study the transcriptome of a limited number of host-mycobacterial
environments; the challenge for the next few years will be to integrate these datasets with
expression data from additional infection models to elucidate host and tissue specific
responses. The investigation of (relatively) simple in vitro or tissue culture models should
help us to understand the transcriptional events from complex environments such as the
murine or human lung. In addition the introduction of bacterial RNA amplification methods
will allow the investigation of smaller, highly defined populations of bacilli from in vivo.
Whole genome technologies offer exciting prospects for the future, such as the integration of
expression data with transcriptional regulation data from emerging technologies such as
ChIP/chip to identify global networks of expression that are important during infection; or in
combination with gene knockout/knockdown technologies to investigate the effects of
individual gene inactivation on the M. tuberculosis transcriptome during infection. All of
this should aid in the understanding of M. tuberculosis natural infection and contribute to
drug development programmes.
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ABBREVIATIONS
RT-PCR Reverse transcription-polymerase chain reaction
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TLR Toll-like receptor
SCOTS Selective capture of transcribed sequences
NOS2 Nitric oxide synthase 2
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Fig. (1).
An illustration of the broad transcriptional responses of M. tuberculosis to the intracellular
environments of naïve and IFNγ-activated macrophages. Macrophage activation
(highlighted by phagolysosome fusion) exposes intracellular bacilli to nitric oxide, and
results in decreased mycobacterial survival. Adapted from [21].
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Fig. (2).
An illustration of the possible microenvironments that M. tuberculosis may encounter on
infection as inferred from the transcriptional data discussed in this review.
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